The Readout

The Readout By Damian Garde

Lilly’s FDA gamble, Biogen’s would-be windfall, & GSK’s existential malaise

The Readout By Damian Garde

TIGIT’s latest twist, Biogen breaks its silence, & the future of GSK

The Readout By Damian Garde

Inside the FDA’s Aduhelm decision, GSK’s pitch for the future, & a biopharma gadfly joins the industry

The Readout By Damian Garde

Aduhelm’s other profiteers, the latest SPAC merger, & BIO’s CEO on FDA rumors

The Readout By Damian Garde

Calif. law failed to increase generic drug use, EU loses bid against AstraZeneca, & a medical journal goes to battle against a journal

The Readout By Damian Garde

Biotech CEO suspended over altered data probe, Biden’s $3.2B plan for Covid pills, & the booster shot debate

The Readout By Meghana Keshavan

GSK’s new immunotherapy, new Novavax data, & more aducanumab ire

The Readout By Meghana Keshavan

Early CAR-T optimism, Vertex shelves a drug & ALS advocates are angry

The Readout By Damian Garde

How the FDA thought about Aduhelm, SPACs explained, & June’s biotech binaries

The Readout By Damian Garde

Biogen’s FDA fallout, pharma’s D.C. clout, & all things Aduhelm

The Readout By Damian Garde

FDA’s momentous Biogen decision, a new day in Alzheimer’s, & Shkreli’s reprieve

The Readout By Damian Garde and Meghana Keshavan

Biogen’s big day, an EU vaccine plan, & an NK trial win

The Readout By Meghana Keshavan

Post-op Keytruda, preventing recurrent breast cancer, & Shkreli undone

The Readout By Damian Garde

Biotech’s buyout fizzle, a parent-sponsored clinical trial, & CureVac’s curious tweet

The Readout By Damian Garde

FDA conspiracy theories, closing the Covid vaccine gap, & how to value a Vant

The Readout By Damian Garde

Digital health bootcamp, a KRAS approval, & aducanumab misgivings

The Readout By Meghana Keshavan

Pfizer’s profitable slowdown, Lilly under scrutiny, & reversing a grandfathering rule

The Readout By Damian Garde

CureVac’s any-day-now data, more FDA conservatism, & a lawsuit about coupons

The Readout By Damian Garde

A middle path for aducanumab, losing money on the biotech boom, & the importance of subject lines

The Readout By Damian Garde

The NASH gold rush is waning, Zolgensma turns 2, & the dawn of federal biotech bonds

The Readout By Meghana Keshavan

Single-cell pediatrics, G20’s Covid-19 focus, & a new CEO for Freenome

The Readout By Damian Garde and Meghana Keshavan

Biotech meme stocks, price competition in immunotherapy, & a heart-shaped mass of stem cells

The Readout By Damian Garde

The latest in CAR-T, Iovance’s rough 24 hours, & a copyright fight in gene therapy

The Readout By Damian Garde

Most Read

Pfizer’s 95% vaccine efficacy, disappointment in ALS, & FDA promises of transparency

Sage’s debatable data, Hahn’s retort, & biotech’s mixed record in June

Covid-19 vaccine data from Novavax & the future of peanut allergy treatment

CureVac’s Covid-19 disappointment, a NICE for U.S., & Biogen’s other Alzheimer’s treatment

CRISPR for cancer, Biogen’s $800m flyer, & Hahn’s VC future

Trump’s drug EO, a $1 billion Biogen deal, & the case for inaccuracy

The saga of a ‘criminal’ short report, Moderna’s valuation, & UniQure’s patents

Another blow to the amyloid theory & Covid-19 testing troubles

All Coverage

Lilly’s FDA gamble, Biogen’s would-be windfall, & GSK’s existential malaise

TIGIT’s latest twist, Biogen breaks its silence, & the future of GSK

Inside the FDA’s Aduhelm decision, GSK’s pitch for the future, & a biopharma gadfly joins the industry

Aduhelm’s other profiteers, the latest SPAC merger, & BIO’s CEO on FDA rumors

Calif. law failed to increase generic drug use, EU loses bid against AstraZeneca, & a medical journal goes to battle against a journal

Biotech CEO suspended over altered data probe, Biden’s $3.2B plan for Covid pills, & the booster shot debate

GSK’s new immunotherapy, new Novavax data, & more aducanumab ire

Early CAR-T optimism, Vertex shelves a drug & ALS advocates are angry

How the FDA thought about Aduhelm, SPACs explained, & June’s biotech binaries

Biogen’s FDA fallout, pharma’s D.C. clout, & all things Aduhelm

FDA’s momentous Biogen decision, a new day in Alzheimer’s, & Shkreli’s reprieve

Biogen’s big day, an EU vaccine plan, & an NK trial win

Post-op Keytruda, preventing recurrent breast cancer, & Shkreli undone

Biotech’s buyout fizzle, a parent-sponsored clinical trial, & CureVac’s curious tweet

FDA conspiracy theories, closing the Covid vaccine gap, & how to value a Vant

Digital health bootcamp, a KRAS approval, & aducanumab misgivings

Pfizer’s profitable slowdown, Lilly under scrutiny, & reversing a grandfathering rule

CureVac’s any-day-now data, more FDA conservatism, & a lawsuit about coupons

A middle path for aducanumab, losing money on the biotech boom, & the importance of subject lines

The NASH gold rush is waning, Zolgensma turns 2, & the dawn of federal biotech bonds

Single-cell pediatrics, G20’s Covid-19 focus, & a new CEO for Freenome

Biotech meme stocks, price competition in immunotherapy, & a heart-shaped mass of stem cells

The latest in CAR-T, Iovance’s rough 24 hours, & a copyright fight in gene therapy

AbbVie’s failed pop quiz, Sarepta’s incremental victory, & pharma’s cyber risk